Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
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
8AUX4j9hy83Wx5KS
Listen
